Catalyst
Slingshot members are tracking this event:
First Patient Enrolled in Mallinckrodt Phase 3 CONFIRM Study to Assess Efficacy and Safety of Terlipressin in Hepatorenal Syndrome Type 1
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| MNK |
|
|
||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Jul 28, 2016
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Terlipressin, Confirm Study, Hepatorenal Syndrome Type 1
